{"nct_id":"NCT05319730","title":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","status":"RECRUITING","status_verified_date":"2025-09","start_date":"2023-05-16","start_date_type":"ACTUAL","primary_completion_date":"2026-11-07","primary_completion_date_type":"ESTIMATED","completion_date":"2029-04-10","completion_date_type":"ESTIMATED","phases":["PHASE1","PHASE2"],"tickers":["MRK"]}